Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

Linking HCV infected people with care is key to reducing related mortality and morbidity

Broader screening to identify people infected with hepatitis C virus (HCV) would likely be cost effective, according to a new report published in Clinical Infectious Diseases.

15 Mar 2012

USPTO issues patent to iSonea's ultrasound-based cough detector

Medical technology company iSonea Ltd. today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 2009/0216127 A1 covering its cough count technology in the field of acoustic monitoring of respiratory diseases.

15 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012

Insmed fourth quarter revenues increase to $1.4 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.

13 Mar 2012

New research could provide roadmap for more effective drug discovery for CF

A recent study led by Gergely Lukacs, a professor at McGill University's Faculty of Medicine, Department of Physiology, and published in the January issue of Cell, has shown that restoring normal function to the mutant gene product responsible for cystic fibrosis (CF) requires correcting two distinct structural defects. This finding could point to more effective therapeutic strategies for CF in the future.

12 Mar 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0M

GenMark Diagnostics, Inc. today reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2011. The Company will release its full financial statements and related disclosures along with its Form 10-K filing for the period ending December 31, 2011 upon completion of its independent audit, which includes the Company's first Sarbanes-Oxley audit of internal controls, by March 15, 2012.

9 Mar 2012

Queen's receives NICH&S grant to create vaccine against Pseudomonas

Queen's University Belfast scientists working on a vaccine to combat Pseudomonas have received a financial boost from Northern Ireland Chest Heart and Stroke.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

Altogen launches new pancreas-targeted in vivo RNAi transfection system

Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals.

7 Mar 2012

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, a peer-reviewed journal from Mary Ann Liebert, Inc.

1 Mar 2012

Ultrasound-based TE more accurate in detecting hepatic fibrosis

Researchers from the Mayo Clinic confirm that ultrasound-based transient elastography (TE) provides excellent diagnostic accuracy for detecting cirrhosis due to recurrent infection with hepatitis C virus (HCV) infection following liver transplantation.

1 Mar 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

Forest Laboratories' Colobreathe dry powder inhaler receives EMA approval

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.

24 Feb 2012

Pediatricians should screen all children for vitamin D deficiency

As study after study shows the fundamental role vitamin D plays in disease and health, vitamin D deficiency — which often develops insidiously in childhood — should be on every parent's and pediatrician's radar, say physicians from the Johns Hopkins Children's Center.

23 Feb 2012

New preclinical data from Regulus' miR-21 study on kidney fibrosis

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine.

17 Feb 2012

Low choline intake increases risk of liver scarring in menopausal women with NAFLD

Menopausal women with non-alcoholic fatty liver disease (NAFLD) who don't consume enough of the essential nutrient choline appear to be at higher risk for liver scarring, according to research led by scientists at Johns Hopkins Children's Center.

17 Feb 2012

Caffeine consumption reduces risk of advanced fibrosis in NAFLD patients

Caffeine consumption has long been associated with decreased risk of liver disease and reduced fibrosis in patients with chronic liver disease. Now, newly published research confirms that coffee caffeine consumption reduces the risk of advanced fibrosis in those with nonalcoholic fatty liver disease (NAFLD).

3 Feb 2012